1Mantovani A et al. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin lmmunol, 2008, 28:1-3.
2Tillet WS et al. Serological reaction in pneumonia with a non- protein somatic fraction of pnemoncoccus. J Exp Med, 1930, 52: 561-571.
3MacLeod CM et al. The occurrence during acute infections of a protein not normally present in the blood II, isolation and properties of the reactive protein. J Exp Med, 1943, 73:183-191.
4Dhingra R et al. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med, 2007, 120:1054-1062.
5Willeke F et al. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer, 2006, 42:2639-2646.
6Miyake K et al. Serum evaluation of soluble interferon-α/βreceptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine, 201 O, 49:251-255.
7Wang CS et al. C-reactive protein and malignancy: clinic- pathological association and therapeutic implication. Chang Gung MedJ, 2009, 32:471-482.
8Nagaoka Set al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int, 2007, 27:1091-1097.
9McMillan DC et al. A clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes B colorectal cancer. Br J Cancer, 2010, 103: 970-974.
10Hayashi H et al. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node disection for early gastric cancer. Surg Endosc, 2005, 19:1172-1176.
